This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing data from the TROPION-Breast01 phase 3 clinical trial of Datopotamab deruxtecan in breast cancer

Ticker(s): AZN, DSNKY

Who's the expert?

Institution: StonyBrook Cancer Center

  • Chief, Division of Hematology/Oncology and Associate Director of Clinical and Translational Research at Stony Brook Cancer Center.
  • Manages approximately 10 patients with HR+/HER2- mBC.
  • Clinical research in breast cancer include biomarker discovery including the use of functional imaging for predicting breast cancer risk and response to antitumor therapies and role of non-steroidal anti-inflammatory drugs (NSAIDs) in breast cancer prevention.

Interview Goal
To discuss the current standard of care and the potential of Datopotamab deruxtecan, a TROP2-directed DXd antibody drug conjugate being developed by AstraZeneca and Daiichi Sankyo for the treatment of patients with inoperable or metastatic hormone receptor positive, HER2-low or negative breast cancer.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.